Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025 (GLOBE NEWSWIRE) --  Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty… Read More..

MIAMI, Oct. 09, 2025 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 100 pending and issued patents globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become… Read More..

Investment led by Funicular Funds, LP with insider participation from Sixth Borough Capital $10,000,000 to be invested in the form of convertible debt with a 5-year term at an 11% coupon and a conversion price of $0.75 $10,000,000 (inclusive of $4,250,000 converted from recent debt financing) to be invested in… Read More..